By Marta Catalfamo
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc)
ClinicalTrials.gov Identifier: NCT05080790
Contact: Daniel Pink, Dr. 033631 73527 [email protected]
Contact: Melanie Prause 069 7601 4211 [email protected]
Sponsors and Collaborators
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
EUSA Pharma, Inc.
Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplant
ClinicalTrials.gov Identifier: NCT03941769
Contact: Gheath Al-Atrash 713-563-3324 [email protected]
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Beta Endorphins,Interleukin 1 and Interleukin 38 in Covid Patients Associated With Neuropsychological Manifestations.
ClinicalTrials.gov Identifier: NCT05198388
Contact: somaya redwan younes, master 01099865482 [email protected]
Contact: Eman mosaad zaki, doctor 01065518821 [email protected]
Sponsors and Collaborators
Assiut University
Evaluation of Serum Interleukin-15 and Interleukin-22 Levels in Patients With Non-segmental Vitiligo
ClinicalTrials.gov Identifier: NCT05121532
Sponsor:
Sohag University
Responsible Party: Samah Saeed Badrous, Sohag University
Clinical Study for the Treatment With Interferon-ß-1a (IFNß-1a) of COVID-19 Patients (INTERCOP)
Principal Investigators: Emanuele Bosi, Professor. IRCCS Ospedale San Raffaele. Milano, Italy, 20132
Contact: Patrizia Rovere Querini, Professor Phone: 00390226426768
ClinicalTrials.gov Identifier: NCT04449380
Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients
Principal Investigators: Brahm H. Segal, MD. Roswell Park Cancer Institute. Buffalo, New York, United States, 14263
Contact: Pawel Kalinski, MD, Phone: 716-845-5721
ClinicalTrials.gov Identifier: NCT04379518
Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis
ClinicalTrials.gov Identifier: NCT03720340
Contact: Yuanyuan Chen, Professor +86 13738103808 [email protected]
Sponsors and Collaborators
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
ClinicalTrials.gov Identifier: NCT03030378
Principal Investigator: Diwakar Davar University of Pittsburgh Cancer Institute LAO
Sponsors and Collaborators
National Cancer Institute (NCI)
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd)
ClinicalTrials.gov Identifier: NCT05049798
Contact: Study Contact 844-434-4210 [email protected]
Sponsors and Collaborators
Janssen Pharmaceutica N.V., Belgium
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
ClinicalTrials.gov Identifier: NCT05094570
Contact: Kristin W Wavell Shifflett, BS 4349246874 [email protected]
Contact: Deborah Murphy, BSN 4349823510 [email protected]
Sponsors and Collaborators
University of Virginia
Regeneron Pharmaceuticals
Investigators
Principal Investigator: Larry C Borish, MD University of Virginia
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
ClinicalTrials.gov Identifier: NCT04079088
Contact: US Biogen Clinical Trial Center 866-633-4636 [email protected]
Contact: Global Biogen Clinical Trial Center [email protected]
Sponsors and Collaborators
Biogen
Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV (LIMT-2)
ClinicalTrials.gov Identifier: NCT05070364
Contact: Nicole Ramza, MBA 650-272-6138 [email protected]
Contact: Monica Gangal, MSc 650-272-6138 [email protected]
Sponsors and Collaborators
Eiger BioPharmaceuticals
Serum IL 26 as a Marker of Disease Activity in SLE
ClinicalTrials.gov Identifier: NCT05161988
Contact: Fatma Al-zahraa M. Abdel-bary, resident 0201014363853 [email protected]
Contact: Sherif H. Jalal, professor 0201222675000 [email protected]
Sponsors and Collaborators
Assiut University
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
ClinicalTrials.gov Identifier: NCT04979052
Contact: Frank vd Veerdonk, Dr. 0031243618819 [email protected]